Key Highlights
● Shares slipped again on November 19 after a steep drop the day before.
● The CMS audit proposal applies across insurers and does not single out Elevance.
● Elevance operates Blue Cross Blue Shield-branded plans in a number of states.
● UnitedHealth Group fell sharply again while Humana and Centene lost ground.
Elevance Health (NYSE:ELV) slipped again on Thursday, November 19, after a steep drop the day before, as a Medicare Advantage audit proposal kept managed-care stocks on the defensive.
The slide continues
Elevance Health declined in Thursday's session, extending a sell-off that gathered force on Wednesday, when the stock sank. The latest decline was smaller, but it showed that investors were not yet ready to step back into managed care. Market reports tied the selling to a proposal from the Centers for Medicare & Medicaid Services (CMS) to widen audits of Medicare Advantage plans.
The proposal is industry-wide. It is a regulatory step that, if adopted, would apply across insurers offering Medicare Advantage plans, and it does not single out Elevance or any other company. Still, the group moved as one: UnitedHealth (NYSE:UNH) Group fell sharply again, while Humana (NYSE:HUM) and Centene (NYSE:CNC) also lost ground.
A diversified insurer, still exposed
Indianapolis-based Elevance is one of the largest US health insurers. It operates Blue Cross Blue Shield-branded plans in a number of states, serving employers, individuals, Medicaid enrollees and Medicare beneficiaries. It also has a health services Business that spans pharmacy benefits and care management.
That mix can make Elevance less dependent on Medicare Advantage than some rivals, but the program is still a meaningful part of its business. When regulators signal tougher scrutiny of how plans are paid, investors often trim exposure across the whole group first and sort out the differences between companies later. That pattern was on display this week, as insurers with very different business mixes traded in near lockstep.
The market backdrop
Thursday offered little shelter. The S&P 500 slid 147.80 points to 7,175.83, a sixth straight losing session and the longest such streak since April 2024, and the index closed below its 200-day moving average, according to market data. The Dow Jones Industrial Average lost 1,101.11 points to 49,097.06, with only one of its 30 components rising, according to market data. The Nasdaq Composite dropped 550.69 points to 23,879.20, and the Russell 2000 slid 59.20 points to 2,655.11.
Stocks had started the day higher before reversing around midday, after Anthropic (NASDAQ:ANT)'s record IPO faded from its first trade. "It has failed to rekindle enthusiasm for tech stocks," one market economist said. Health care, often treated as a defensive corner of the market, offered no refuge from the selling, with drugmakers such as Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) falling alongside the insurers.
Data also weighed. Jobless claims came in at 203,000, above forecasts, while the Philadelphia Fed Manufacturing index fell to 6.3, its lowest in six months, even as its prices-paid measure jumped. Fed minutes released Wednesday showed nearly all officials see more rate increases as likely needed, according to market data. Futures-market pricing pointed to a quarter-point December hike as very likely, with a smaller chance of a half-point move.
What to watch
Elevance's next moves are likely to depend on how the CMS proposal develops. Investors will watch for the agency's next steps, industry responses and any clearer sense of how wider audits would work in practice. Proposals can be modified before they take effect, and the final shape of the rule remains uncertain. Beyond managed care, the Fed's December 8–9 meeting and November Inflation figures due December 10 will set the tone for a wider market that has now fallen for six sessions in a row and is looking for a reason to stabilize.






Please wait processing your request...